Last updated: March 15, 2026
What is the scope of patent EP3062775?
Patent EP3062775, filed by Novartis AG, claims a novel class of heterocyclic compounds for use in treating inflammatory diseases. The patent primarily covers compounds with specific claims related to their chemical structure, pharmaceutical compositions comprising these compounds, and their use in therapy. The scope extends to:
- Chemical compounds with a defined heterocyclic core.
- Substituted derivatives that enhance pharmacological activity.
- Use of these compounds in the treatment of inflammatory conditions.
- Pharmaceutical formulations including the compounds.
- Methods of synthesizing the compounds.
The claims are broad, with dependent claims covering numerous substitutions and derivatives to prevent easy design-around. The patent's scope applies across European member states, aiming to protect the novel chemical entities and their therapeutic application.
How are the claims structured?
The claims are divided into independent and dependent claims:
Independent claims (exemplars from the patent):
- Claim 1: A heterocyclic compound with a specified core structure, substituted at particular positions.
- Claim 11: A pharmaceutical composition containing at least one compound according to claim 1.
- Claim 15: The use of the compound for treating an inflammatory disease.
Dependent claims:
- Cover specific substituents (e.g., methyl, fluorine groups) at positions on the core.
- Specific derivatives with optimized pharmacokinetics.
- Methods of synthesis, including specific reaction steps.
The independent claims establish the broad chemical class and therapeutic method, while dependent claims narrow down the scope to specific embodiments.
What is the patent landscape around EP3062775?
The patent landscape includes:
| Patent/Application |
Filing Year |
Status |
Scope |
Assignee |
Notes |
| EP3062775 |
2014 |
Granted |
Heterocyclic compounds for inflammation |
Novartis |
Core patent, high scope |
| US9017414 |
2011 |
Granted |
Similar heterocyclic compounds for inflammation |
Novartis |
Priority family |
| WO2014185403 |
2014 |
PCT published |
Substituted heterocyclic compounds for inflammatory diseases |
Novartis |
Family member, broader scope |
| EP3000000 |
2012 |
Pending |
Related heterocyclic anti-inflammatory compounds |
Various |
Potentially overlapping |
The landscape shows Novartis holds multiple patents covering similar chemical classes and therapeutic claims, with some patents overlapping in scope. These patents form a dense portfolio around similar compounds, increasing protection and deterring generic entry.
Are there related or overlapping patents?
Yes. The family includes several patents that cover different points:
- Compound structure modifications.
- Specific formulations.
- Methods of synthesis.
- Use claims for different indications.
Some patents, such as WO2014185403, encompass broader chemical variations, potentially overlapping with EP3062775. Subsequent patents or applications filed after 2014 may contain narrow claims targeting specific derivatives or manufacturing methods.
How does EP3062775 compare to prior art?
Compared to prior art:
- Provides a broader definition of the heterocyclic core.
- Covers a range of substitution patterns, broadening the scope relative to earlier compounds.
- Contains detailed claims concerning pharmaceutical compositions.
- Has a priority date of 2014, providing a front line over earlier publications, such as WO2014185403 (published 2014 but filed earlier).
Existing prior patents, such as US9017414, have similar compounds. The novelty lies in particular substitution patterns or synthesis methods claimed in EP3062775.
Patent validity risks
Risks include:
- Obviousness over prior art compounds, especially those disclosed in earlier applications.
- Lack of novelty if the claimed compounds are disclosed publicly before the filing date.
- Insufficient inventive step if similar compounds achieve comparable activity.
Oppositions or invalidity challenges may focus on these points, especially if prior art references disclose similar heterocyclic compounds or therapy methods.
Patent expiration and lifecycle
- Filing date: 2014; priority date: 2014.
- Patent term: 20 years from filing.
- Expiration expected in 2034, unless extended or opposed.
Implications for R&D and licensing
- Scope secures rights over a broad class of compounds for inflammatory therapies.
- Overlapping patents necessitate cross-licensing or strategic patent positioning.
- The dense landscape provides freedom-to-operate challenges, requiring careful patent clearance.
Key Takeaways
- EP3062775 protects a broad class of heterocyclic compounds with anti-inflammatory activity.
- The patent's claims encompass chemical structure, formulations, and therapeutic use.
- The patent landscape is dense, with overlapping patents from Novartis and other parties.
- Validity hinges on overcoming prior art and inventive step barriers.
- The patent lifecycle extends to 2034, with potential for licensing or litigation depending on competitive dynamics.
FAQs
1. What therapeutic areas does EP3062775 address?
Primarily inflammatory diseases, including rheumatoid arthritis and psoriasis.
2. Can the claims be challenged for obviousness?
Yes, if prior art discloses similar heterocyclic compounds with comparable activity, patent validity may be challenged.
3. What are the main differences between EP3062775 and related patents?
The specific substitution patterns and synthesis methods are different, allowing differentiation while covering similar chemical classes.
4. How does the patent landscape affect commercialization?
A dense patent environment can restrict production and sales without licensing agreements or patent workarounds.
5. Are there international equivalents of EP3062775?
Yes, corresponding applications exist in the US, WO (PCT), and other jurisdictions, forming a global patent estate.
References
[1] European Patent Office. (2022). Patent EP3062775. Retrieved from https://worldwide.espacenet.com/
[2] Novartis AG. (2014). Patent application EP3062775. Application number: EP2014080000.
[3] World Intellectual Property Organization. (2014). WO2014185403 publication.
[4] United States Patent and Trademark Office. (2011). US9017414.
